Trial Profile
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Mar 2020
Price :
$35
*
At a glance
- Drugs Remestemcel-L (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors Mesoblast; Osiris Therapeutics
- 06 Mar 2020 Status changed from active, no longer recruiting to completed.
- 07 Dec 2017 Planned End Date changed from 1 Jul 2017 to 1 Feb 2019.
- 07 Dec 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Feb 2019.